Cargando…

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis

Dissociated agonists of the glucocorticoid receptor (DAGRs) show similar antiinflammatory effects but improved tolerability compared with standard glucocorticoid receptor (GR) agonists. The prodrug fosdagrocorat (PF‐04171327), with active DAGR metabolite PF‐00251802 (Metabolite‐1), is postulated to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weatherley, Barry, McFadyen, Lynn, Tammara, Brinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759734/ https://www.ncbi.nlm.nih.gov/pubmed/29106053 http://dx.doi.org/10.1111/cts.12515

Ejemplares similares

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study
por: Stock, Thomas, et al.
Publicado: (2017)

In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor
por: Ripp, Sharon L., et al.
Publicado: (2017)

Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics
por: Shoji, S, et al.
Publicado: (2017)

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
por: Chan, Phylinda L. S., et al.
Publicado: (2010)

Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
por: Nayak, Satyaprakash, et al.
Publicado: (2021)

A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2016)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
por: Jacqmin, P, et al.
Publicado: (2013)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Pregabalin Population Pharmacokinetic and Exposure‐Response Analyses for Focal Onset Seizures in Children (4–16 years) and Adults, to Support Dose Recommendations in Children
por: Chan, Phylinda L. S., et al.
Publicado: (2021)

Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis
por: Venter, Gabriella, et al.
Publicado: (2021)

Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis
por: van Oosten, Manon JM, et al.
Publicado: (2010)

In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis
por: Quax, Rogier AM, et al.
Publicado: (2012)

Glucocorticoid receptor gene polymorphisms and susceptibility to rheumatoid arthritis
por: Donn, Rachelle, et al.
Publicado: (2007)

Why and how to optimize glucocorticoid treatment in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2012)

The use of glucocorticoids in rheumatoid arthritis - no 'rational' approach yet
por: Desai, Sonali P, et al.
Publicado: (2010)

Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
por: Makrygiannakis, Dimitrios, et al.
Publicado: (2012)

Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
por: Verhoeven, Frank, et al.
Publicado: (2016)

Glucocorticoid management in rheumatoid arthritis: morning or night low dose?
por: Paolino, Sabrina, et al.
Publicado: (2017)

292 Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
por: Wallace, Beth, et al.
Publicado: (2022)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider
por: Boers, Maarten
Publicado: (2023)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
por: Williams, Jason H., et al.
Publicado: (2016)

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling
por: Jacqmin, Philippe, et al.
Publicado: (2010)

Dose Selection Based on Modeling and Simulation for Rivipansel in Pediatric Patients Aged 6 to 11 Years With Sickle Cell Disease
por: Tammara, Brinda K., et al.
Publicado: (2017)

Investigating the Subcortical Route to the Amygdala Across Species and in Disordered Fear Responses
por: McFadyen, Jessica
Publicado: (2019)

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy
por: Aeberli, Daniel, et al.
Publicado: (2013)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis
por: Honne, Kyoko, et al.
Publicado: (2015)

Rheumatoid arthritis - a neuroendocrine immune disorder: glucocorticoid resistance, relative glucocorticoid deficiency, low-dose glucocorticoid therapy, and insulin resistance
por: Straub, Rainer H
Publicado: (2014)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Major depressive disorders in patients with inflammatory bowel disease and rheumatoid arthritis
por: Haider, Maryam Bilal, et al.
Publicado: (2023)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes
por: McFadyen, James D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9bjgql061q7bpeblnveio2q1v5